RecruitingNot ApplicableNCT05792007

Study of the Medullary Microenvironment in Acute Childhood Leukemia

Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant


Sponsor

University Hospital, Tours

Enrollment

40 participants

Start Date

Oct 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.


Eligibility

Min Age: 1 YearMax Age: 15 Years

Inclusion Criteria13

  • for patients with AL:
  • Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
  • Not having received prior hematological treatment
  • Aged 1 to 15 years old
  • Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
  • Affiliated patient or beneficiary of a social security scheme.
  • Control group patients:
  • Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
  • Aged between 1 and 15 years old.
  • Having no pathology of hematological origin.
  • Not having received any treatment that could interfere with the functioning of the bone marrow.
  • Whose 2 parents or the holder of parental authority have signed a consent enlightened.
  • Affiliated patient or beneficiary of a social security scheme.

Exclusion Criteria13

  • for patients with AL:
  • Patient under 1 year old and over 15 years old.
  • Contraindication to myelogram.
  • Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
  • Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
  • Having received prior hematological treatments.
  • Parents with physical or mental condition not allowing to understand the informed consent.
  • Control group patients
  • Patient under 1 year old and over 15 years old.
  • Having an underlying haematological pathology.
  • Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
  • Having received prior hematological treatments.
  • Parents with physical or mental condition not allowing to understand informed consent.

Interventions

PROCEDUREBiological sampling in patients

blood and bone marrow samples from patients with Acute Leulemia.

PROCEDUREBiological sampling in control patients

blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).


Locations(3)

Service d'hématologie biologique-CHRU TOURS

Tours, France

Service d'onco-hématologie pédiatrique -CHRU Tours

Tours, France

Service de chirurgie orthopédique pédiatrique -CHRU TOURS

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05792007


Related Trials